**Question:** All of the following are true except about GLP-1 analogues except?

A. GLP-1 analogues are used to treat type 2 diabetes.
B. GLP-1 analogues stimulate insulin secretion.
C. GLP-1 analogues inhibit glucagon secretion.
D. GLP-1 analogues are not associated with weight loss.

**Core Concept:** GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone that plays a vital role in regulating glucose homeostasis by stimulating insulin secretion, inhibiting glucagon secretion, and slowing gastric emptying. GLP-1 analogues are synthetic versions of GLP-1 designed to mimic its effects and improve glycaemic control in patients with type 2 diabetes.

**Why the Correct Answer is Right:** Option D is incorrect because GLP-1 analogues do contribute to weight loss, albeit as a secondary effect. They reduce food intake by affecting the central nervous system, inhibiting gastric emptying, and promoting satiety.

**Why Each Wrong Option is Incorrect:**

A. GLP-1 analogues are indeed used to treat type 2 diabetes, as they help improve glycaemic control by enhancing insulin secretion and suppressing glucagon release.

B. Although GLP-1 stimulates insulin secretion, this option is incorrect because its primary purpose is to regulate glucose homeostasis, not stimulate insulin specifically.

C. GLP-1 analogues do inhibit glucagon secretion, which is a key mechanism by which they help manage diabetes.

**Why the Correct Answer is Right:**

Option D ("not associated with weight loss") is the correct answer because GLP-1 analogues contribute to weight loss as a secondary effect. They reduce food intake and promote satiety, leading to weight loss.

**Why Each Wrong Option is Incorrect:**

A. GLP-1 analogues do contribute to weight loss as a secondary effect, but the primary purpose is to regulate glucose homeostasis and improve glycaemic control in patients with type 2 diabetes.
B. Although GLP-1 stimulates insulin secretion, this option is incorrect because the primary purpose of GLP-1 analogues is to regulate glucose homeostasis, not stimulate insulin specifically.
C. GLP-1 analogues inhibit glucagon secretion, which is a key mechanism by which they help manage diabetes.

**Clinical Pearl:** GLP-1 analogues, such as dulaglutide and liraglutide, are commonly used in the treatment of type 2 diabetes. They exert their therapeutic effects through mechanisms like glucose-dependent insulin secretion, inhibition of glucagon release, and slowing of gastric emptying. While these actions help manage diabetes, the weight loss effect is a secondary outcome and should not be solely relied upon for therapeutic decision-making.